Capricor Therapeutics (CAPR) Operating Leases (2021 - 2025)
Historic Operating Leases for Capricor Therapeutics (CAPR) over the last 5 years, with Q3 2025 value amounting to $14.4 million.
- Capricor Therapeutics' Operating Leases rose 162749.85% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year increase of 162749.85%. This contributed to the annual value of $616315.0 for FY2024, which is 5854.71% down from last year.
- Capricor Therapeutics' Operating Leases amounted to $14.4 million in Q3 2025, which was up 162749.85% from $194603.0 recorded in Q2 2025.
- Capricor Therapeutics' Operating Leases' 5-year high stood at $14.4 million during Q3 2025, with a 5-year trough of $194603.0 in Q2 2025.
- For the 5-year period, Capricor Therapeutics' Operating Leases averaged around $2.3 million, with its median value being $1.6 million (2023).
- Data for Capricor Therapeutics' Operating Leases shows a peak YoY increase of 162749.85% (in 2025) and a maximum YoY decrease of 8136.18% (in 2025) over the last 5 years.
- Capricor Therapeutics' Operating Leases (Quarter) stood at $2.5 million in 2021, then decreased by 23.43% to $1.9 million in 2022, then fell by 20.83% to $1.5 million in 2023, then tumbled by 58.55% to $616315.0 in 2024, then skyrocketed by 2240.15% to $14.4 million in 2025.
- Its Operating Leases stands at $14.4 million for Q3 2025, versus $194603.0 for Q2 2025 and $407392.0 for Q1 2025.